|
STAT3 inhibitor | Structure | Mechanism of inhibition |
|
(1) Curcumin | | Inhibits STAT3 activation and STAT3 DNA binding |
|
(2) Resveratrol | | Inhibition of STAT3 activation and STAT3-regulated signaling pathway |
|
(3) Cucurbitacin derivatives | Structure of various cucurbitacin derivatives | Mechanism of inhibition |
|
Cucurbitacin I | | Inhibition of STAT3 binding to DNA and gene transcription |
|
Cucurbitacin B | | Inhibition of STAT3 activation and STAT3 binding to DNA |
|
Cucurbitacin E | | Inhibition of STAT3 activation and gene expression |
|
Cucurbitacin Q | | Inhibition of STAT3 activation without inhibition in JAK2 |
|
(4) Flavopiridol | | Disrupts STAT3/DNA interactions and inhibits STAT3 gene transcription and translation |
|
(5) Deoxytetrangomycin | | Abrogates STAT3 dimerization, STAT3 nuclear translocation and STAT3 DNA binding |
|
(6) Cyclopentenone Derivatives | | Inhibits tyrosine phosphorylation of STAT3, STAT1 and serine phosphorylation of STAT3 |
|
(7) N-Acyl homoserine lactone | | Inhibition of STAT3 activation |
|
(8) Indirubin derivatives | Structure of various indirubin derivatives | Mechanism of inhibition |
|
E804 | | Inhibition of STAT3 activation and STAT3 gene expression |
|
6-Bromoindirubin-3-oxime | | Inhibition of STAT3 activation and STAT3 gene expression |
|
| | Inhibition of STAT3 activation |
|
(9) Tyrphostin/AG490 | | Inhibition of STAT3 activation and STAT3-DNA binding |
|
(10) Platinum-containing compounds and their derivatives | Structure of various platinum containing compounds | Mechanism of inhibition |
|
Cisplatin | | Dephosphorylation of JAK2/STAT3 |
|
CPA-1 | | Inhibition of STAT3 activation and STAT3-DNA binding |
|
CPA-7 | | Inhibition of STAT3 activation and STAT3-DNA binding |
|
(11) Atiprimod | | Inhibition of STAT3 activation |
|
(12) Pentoxifylline | | Inhibition of STAT3 activation, STAT3 nuclear translocation and STAT3-DNA binding |
|